Emgality is a calcitonin gene-related peptide (CGRP) binding antibody studied in migraine and episodic cluster headache1
Emgality is a humanized monoclonal antibody that binds to CGRP and blocks its binding to the receptor1

There are no relevant data on the pharmacodynamic effects of galcanezumab-gnlm.1
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Emgality works differently than many other preventive medications because it was specifically developed to bind to CGRP, a substance in the brain that may play a key role in migraine1-3
View real-world refill rate equivalent data for select preventive migraine medications
Reference: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-552. 3. Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatr Dis Treat. 2006;2(3):281-291.